Skip to main content

Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to Candida parapsilosis and Candida albicans

From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex

Variables

Patients with BSIs due to:

C. parapsilosis (n = 63)

C. albicans (n = 146)

P valuea

Age (years), median (IQR)b

67 (43–76)

51 (66–77)

0.133

Neonates (<3 months)

1 (2)

5 (3)

0.465

Elderly (>65 years)

32 (51)

72 (49)

0.844

Male sex, n (%)

35 (56)

91 (63)

0.358

Ward

 Internal Medicine, n (%)

25 (40)

52 (36)

0.448

 Surgery, n (%)

17 (27)

32 (22)

 

 Intensive Care Unit, n (%)

21 (33)

62 (43)

 

Comorbidities, n (%)

57 (90)

137 (94)

0.387

 Chronic pulmonary diseases, n (%)c

9 (14)

11 (8)

0.127

 Haematological malignancy, n (%)

1 (2)

8 (5)

0.203

 Cardiovascular diseases, n (%)d

27 (43)

67 (46)

0.685

 Neurological diseases, n (%)e

10 (16)

24 (16)

0.919

 Gastrointestinal diseases, n (%)f

21 (33)

43 (29)

0.576

 Diabetes mellitus, n (%)

8 (13)

28 (19)

0.254

 Solid tumors, n (%)

15 (24)

43 (30)

0.403

 Chronic renal failure, n (%)

7 (11)

12 (8)

0.504

Previous surgery (<30 days), n (%)

32 (51)

67 (46)

0.514

 Gastrointestinal surgery, n (%)

8 (13)

19 (13)

0.950

 Cardiovascular surgery, n (%)

13 (21)

28 (19)

0.807

 Other surgery, n (%) g

12 (19)

24 (16)

0.646

Central venous catheter, n (%)

56 (89)

127 (87)

0.702

 BSI CVC-related, n (%)

36 (64)

57 (45)

0.015

Other devices, n (%)h

57 (90)

129 (88)

0.653

Previous invasive procedures (<72 h), n (%)i

16 (25)

44 (30)

0.486

Parenteral nutrition, n (%)

43 (68)

105 (72)

0.592

Immunosuppressive therapy, n (%)j

18 (29)

56 (34)

0.174

Neutropenia, n (%)

4 (6)

7 (5)

0.644

Septic shock, n (%)

2 (3)

12 (8)

0.180

Prior antibiotic therapy, n (%)

58 (92)

139 (95)

0.370

Previous antifungal therapy (<30 days), n (%)

5 (8)

21 (14)

0.195

Concomitant bacteriemia, n (%)

15 (24)

40 (27)

0.588

Other coinfections, n (%)k

39 (62)

89 (61)

0.897

Appropriate antifungal therapy, n (%)l

38 (60)

92 (63)

0.712

 Primary azole therapy

41 (65)

77 (53)

0.098

 Primary echinocandin therapy

7 (11)

34 (23)

0.041

 Primary polyene therapy

1 (2)

3 (2)

0.820

 None

14 (22)

32 (22)

0.961

Overall mortality, n (%)

17 (27)

61 (42)

0.042

 Early mortality (days 1–7), n (%)

4 (6)

24 (17)

0.049

 Late mortality (days 8–30), n (%)

13 (21)

37 (25)

0.464

  1. aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables
  2. bIQR, Interquartile range
  3. cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
  4. dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
  5. eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
  6. fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
  7. g Other surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
  8. h Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
  9. iPrevious invasive procedures include endoscopy and positioning of any device
  10. jImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
  11. kOther coinfections include bacterial and/or fungal infections in sites other than blood
  12. lAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started ≤ 72 h from the first blood culture performed